FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average b	ourden									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

1. Name and Address of Reporting Person*  Megna Michael R  (Last) (First) (Middle)  C/O KINIKSA PHARMACEUTICALS, LTD.  CLARENDON HOUSE 2 CHURCH STREET				Susuer Name and Ticker or Trading Symbol Kiniksa Pharmaceuticals, Ltd. [ KNSA ]      Date of Earliest Transaction (Month/Day/Year)     03/20/2021								(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner  X Officer (give title Other (specify below) Chief Accounting Officer					
(Street) HAMILTON D0 HM11 (City) (State) (Zip)				4. If Amendment, Date of Original Filed (Month/Day/Year)							Lin	Individual or Joint/Group Filing (Check Applicable Line)      X Form filed by One Reporting Person     Form filed by More than One Reporting Person						
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				2A. Deemed Execution Date,		3. Transa Code (I	ction	4. Securities Acqui Disposed Of (D) (In 5)		red (A) or str. 3, 4 an	5. Amou Securitie Benefici Owned I Reporte	. Amount of ecurities For (Diversity length of the control of the		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any		c	ransaction of Code (Instr. Derivative			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4		Beneficial Ownership (Instr. 4)			
				C	ode	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Amount or Number of Shares					
Restricted Share Units	(1)	03/20/2021			A		3,231		(2)		(2)	Class A Common Shares	3,231	\$0	3,231		D	
Restricted Share Units	(1)	03/20/2021			A		2,163		(3)		(3)	Class A Common Shares	2,163	\$0	2,163		D	

## Explanation of Responses:

- 1. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
- 2. The performance criteria for these RSUs were met. The RSUs will vest in a single installment on March 20, 2022, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs.
- 3. The performance criteria for these RSUs were met. The RSUs will vest in a single installment on March 20, 2023, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs.

/s/ Thomas W. Beetham,

Attorney-in-Fact For Michael 03/23/2021

R. Megna

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.